COVID-19-mediated pulmonary fibrosis:from mechanisms to medicines

WANG Jie,WU Xue-feng,XU Qiang
DOI: https://doi.org/10.12360/cpb202204087
2023-01-01
Abstract:Coronavirus disease-19(COVID-19),a global epidemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),lead to lung injury in millions of people.SARS-CoV-2 can not only cause cytokine storm,acute respiratory distress syndrome and respiratory failure in the phase of acute infection,but also have potential long-term effects on the lungs.Survivors of severe COVID-19 may develop pulmonary fibrosis,resulting in permanent lung injury. In this review we expound the occurrence and development of COVID-19-related pulmonary fibrosis,summarize the key roles of TGF-β/Smad,TGF-β/MAPK,JAK/STAT,Wnt/β-catenin,YAP/TAZ,NF-κB and PI3K/Akt signal pathways in this process,and analyze the advantages and disadvantages of antiviral drugs,anti-fibrosis drugs,cytokine-targeted drugs,corticosteroids,spironolactone,traditional Chinese medicine prescriptions and lung transplantation in its treatment. This review may provide a reference for the study of pathological mechanism and clinical treatment of COVID-19-related pulmonary fibrosis.
What problem does this paper attempt to address?